Chinese company Sinovac has come up with CoronaVac, a new vaccine for Coronavirus and it has been tested and analyzed by WHO officials and labs. The reports have indicated the safe use of the vaccine. Therefore, WHO has authorized the use of the vaccine in the vaccine sharing program it sponsors, which is known as COVAX. This pharmaceutical company from China is the second company after Sinopharm from China, to be given the green signal. As per the tests conducted, WHO is assured of the safety of the vaccines. WHO Director-General Tedros Adhanom Ghebreyesus said on Tuesday that CoronaVac was “found to be safe, effective, and quality-assured following two doses of the inactivated vaccine.”
Chinese Pharma Company Sinovac Gets WHO Nod To Use CoronaVac As Emergency Shot
The COVAX program plans to provide immunizations at a level where equitable global access is provided. The packing and dispatch of large quantities of this vaccine will be easy as the vaccine does not require storage in super cold temperature, unlike most corona vaccines that we find today.”The easy storage requirements of CoronaVac make it very suitable for low-resource settings,” Tedros said. “It’s now crucial to get these lifesaving tools to the people that need them quickly.”
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has heavily recommended the CoronaVac vaccine for people over 18. Any two doses have to be compulsorily spaced between two and four weeks. It has already been successfully used in Ukraine. It is known to prevent the onset of symptoms of the disease in half of the people that it was vaccinated. It also prevented escalation and hospitalization in 100% of the patients who were given the CoronaVac shot. It successfully prevented severe incidences and therefore is the 8th vaccine to be allowed emergency usage. The previous ones authorized for emergency usage are from AstraZeneca, Pfizer/BioNtech, Moderna, the Serum Institute of India and Janssen (Johnson & Johnson).
There is a heavy need for doses and vaccines that are not uniformly distributed all across the world. There are countries where second doses are still not available and case numbers are surging. There have been complaints of Western countries stockpiling the vaccine doses. The supply from India was halted temporarily, and this was due to a rise in number of cases in India. The AstraZeneca supply, therefore, broke and took some time to replenish itself. “COVAX should have already delivered 170 million total doses,” according to a report from the UN Children’s Fund (UNICEF). However, by May 17, the program has successfully completed 71 million shots to 125 countries and territories.”The world desperately needs multiple Covid-19 vaccines to address the huge access inequity across the globe,” Mariângela Simão, WHO assistant-director general for access to health products, said in a statement. “We urge manufacturers to participate in the COVAX Facility, share their know-how and data and contribute to bringing the pandemic under control.”
The two vaccines from China are not mRNA vaccines as given by Moderna and Pfizer/BioNTech. Both vaccines from Sinopharm and Sinovac are inactive vaccines. Strangely, the Chinese companies have not fully released the worldwide data of administration of the vaccines in different countries. It has been used in Ukraine and other countries which were experiencing less flow in vaccines. The clinical trials were also conducted across the globe and scientists and medical experts have deeply criticized the not sharing of details. In their defence, Sinovac has mentioned that different countries gave different efficacy results to them. However, in every country, there were above 50% efficacy reported, which was essential for them to get WHO’s nod for emergency usage of the vaccine. Countries they have been providing vaccine shots too are the Philippines, Mainland China, Indonesia, Chile, Mexico, Turkey, and Brazil.